SCIENTIFIC PLANNING COMMITTEE Nora Hansen, MD Kalliopi Siziopikou, MD, PhD Jonathan Strauss, MD, MBA SYMPOSIUM CHAIR William Gradishar, MD SYMPOSIUM CO-CHAIR Monica Morrow, MD 22 ND ANNUAL LYNN SAGE BREAST CANCER SYMPOSIUM SEPTEMBER 10 - 12, 2020 VIRTUAL FOR 2020 VISIT OUR WEBSITE lynnsagebreastcancer.org
8
Embed
22 ANNUAL LYNN SAGE BREAST CANCER SYMPOSIUM · Optional Non-CME: Sponsored by Genentech HER2 Positive Early Breast Cancer: Determining Adjuvant Treatment Following Neoadjuvant Therapy
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
SCIENTIFIC PLANNING COMMITTEE Nora Hansen, MD Kalliopi Siziopikou, MD, PhD Jonathan Strauss, MD, MBA
SYMPOSIUM CHAIR William Gradishar, MD SYMPOSIUM CO-CHAIR Monica Morrow, MD
22ND ANNUAL LYNN SAGE BREAST CANCER SYMPOSIUM SEPTEMBER 10 - 12, 2020
VIRTUAL FOR 2020
VISIT OUR WEBSITE lynnsagebreastcancer.org
Referred to as the most valuable breast cancer meeting worldwide for the practicing clinician, the Lynn Sage Breast Cancer Symposium provides 3 days of formal presentations and interactive case discussions. For over 20 years, this multidisciplinary CME program has been bringing together leading national and international medical, surgical, and radiation oncologists to present, debate, and evaluate cutting-edge technology and approaches in the management of breast cancer.
Progress across all aspects of patient care, including prevention, screening, detection and survivorship, as well as in the primary treatment modalities of surgery, radiation therapy, endocrine therapy, cytotoxic chemotherapy and novel biologic therapies are leading to new strategies and therapeutic options. This symposium focuses on the close cooperation required for effective multidisciplinary management of patients with breast cancer.
Educational Objectives
At the conclusion of this activity, participants will be able to:
1. Discuss optimal evaluation and management of women at increased risk for breast cancer.
2. Analyze application of neoadjuvant endocrine therapy in operable cancer.
3. Describe the role of new technology in radiology and radiotherapy.
4. Identify new approaches to systemic therapy and how they may influence surgical management.
Target Audience
The target audience for this activity includes medical oncologists, surgical oncologists, radiation oncologists,internal medicine and other health professionals who interact with or treat breast cancer patients and survivors.
PROGRAM INFORMATION
Session 1: Supportive Care Moderator: Nora Hansen, MD
9:00 am Symposium Welcome William Gradishar, MD, Symposium Chair
9:05 am Managing the Side Effects of Endocrine Therapy Dawn Hershman, MD
9:35 am New Approaches to Pain Management in Breast Surgery Tracy-Ann Moo, MD
10:05 am Current Considerations for Lymphedema Diagnosis and Treatment Sarah McLaughlin, MD
10:35 am Break
10:45 am Delivering Survivorship Care Sheetal Kircher, MD
11:15 am Q&A
11:30 am Lunch Break & Exhibits 11:35 am Optional Non-CME: Sponsored by Lilly A Treatment Option for Patients With HR+, HER2- Advanced or Metastatic Breast Cancer 12:05 pm Break
Session 2: Breast Pathology for the Non-Pathologist Moderator: Kalliopi Siziopikou, MD, PhD
12:10 pm Evaluation of Pathologic Response After Neoadjuvant Chemotherapy: A Continuing Challenge Kalliopi Siziopikou, MD, PhD
1:10 pm WHO Classification of Breast Tumors: The 2019 Update Luis Blanco, Jr., MD
1:40 pm Genomic Tools That Predict Response in Breast Cancer Virginia Kaklamani, MD, DSc 2:10 pm Q&A
2:30 pm Adjourn
SEPTEMBER 10 THURSDAY
Session 4: Breast Imaging and Risk Management Moderator: Seema Khan, MD
9:00 am Update on Contrast Mammography Maxine Jochelson, MD
9:30 am Machine Learning as a Tool to Improve Breast Imaging Connie Lehman, MD, PhD
10:00 am Assessing Genetic Risk 2020 Banu Arun, MD 10:30 am Break
10:45 am Controversies in Surgical Management of BRCA Carriers Mary Gemignani, MD, MPH
11:15 am Genetic Testing in Practice: Perceptions of Patients and Physicians Steven Katz, MD
11:45 am Q&A
12:00 pm Lunch Break & Exhibits 12:05 pm Optional Non-CME: Sponsored by Seattle Genetics A New Treatment in HER2+ Metastatic Breast Cancer 12:35 pm Break
Session 5: New Approaches to Old Problems Moderator: Massimo Cristofanilli, MD
12:40 pm Male Breast Cancer: Is it Really Worse? Anthony Elias, MD
1:10 pm Detection and Treatment of Minimal Residual Disease: The Way Forward? Lajos Pusztai, MD, DPhil
1:40 pm Patterns of Tumor Response Following NAC: Implications for Local Therapy Stuart Schnitt, MD
2:10 pm Break
2:25 pm Proton Radiotherapy for Breast Cancer: Advance or Fad? Jonathan Strauss, MD, MBA
2:55 pm Delay in Breast Cancer Treatment: Is it Harmful? Richard Bleicher, MD
3:25 pm Q&A
3:45 pm Adjourn
SEPTEMBER 11 FRIDAY
8:15 am Optional Non-CME: Sponsored by DSI Updates on the Treatment of Patients With Unresectable or Metastatic HER2+ Breast Cancer Who Previously Received Anti-Her2 Therapies Session 6: Current Approach to Advanced Disease Moderator: William Gradishar, MD
9:00 am Novel Endocrine Agents William Gradishar, MD
9:30 am Update on Brain Metastases Carey Anders, MD
10:00 am Stereotactic Body Radiation Therapy for Oligometastases Steve Chmura, MD, PhD
10:30 am Break
10:45 am Metastatic Triple Negative Breast Cancer Kari Wisinski, MD
11:15 am Surgery of the Primary Tumor in Stage 4 Breast Cancer Seema Khan, MD
11:45 am Q&A
12:00 pm Lunch Break & Exhibits 12:05 pm Optional Non-CME: Sponsored by Genentech HER2 Positive Early Breast Cancer: Determining Adjuvant Treatment Following Neoadjuvant Therapy 12:35 pm Break
Session 7: Emerging Issues in Breast Cancer Management Moderator: Jonathan Strauss, MD, MBA
12:40 pm Financial Toxicity of Breast Cancer Treatment Reshma Jagsi, MD, DPhil
1:10 pm Will Surgery Be a Part of Breast Cancer Therapy in the Future? Monica Morrow, MD
1:40 pm Implant Associated Lymphoma Jonas Nelson, MD
2:10 pm Q&A
2:25 pm Break
Session 8: Issues in Neoadjuvant Therapy Moderator: Monica Morrow, MD
2:40 pm Decision Making for Neoadjuvant Therapy in ER+ Patients Otto Metzger, MD
3:40 pm Radiotherapy Decision Making After Pathological Complete Response Julia White, MD 3:55 pm Q&A
4:00 pm Adjourn
SEPTEMBER 12 SATURDAY
Registration Advance registration is encouraged to ensure prompt access to the Virtual Symposium. The registration fee includes conference tuition, CME credits, MOC points, access to digital materials and networking opportunities. Register online at lynnsagebreastcancer.org.
Type Price
Physician $375
LMIC* Physician $100
Nurse/Nurse Practitioner/Fellow/Other Allied Health $75
LMIC* Nurse/Nurse Practitioner/Fellow/Other Allied Health $25
Industry $595
*Registrants who reside in LMIC countries as defined by the World Bank Group. Refund/Cancellation Policy Registration fees, less a $50 administrative handling fee, are refundable if written request is received on or before August 15, 2020. Please include your registration ID number when requesting a refund. No refunds will be granted after August 15, 2020. However, you may transfer your registration to a colleague. For further information, please call 312-503-7809 or email [email protected].
CONFIRMED FACULTY
Carey Anders, MD Duke University School of Medicine
Banu Arun, MDUniversity of Texas MD Anderson Cancer Center
Luis Blanco, Jr., MDRobert H. LurieComprehensive Cancer Centerof Northwestern University
Richard Bleicher, MDFox Chase Cancer Center
Steven Chmura, MD, PhDUniversity of Chicago Medicine
Massimo Cristofanilli, MDRobert H. LurieComprehensive Cancer Centerof Northwestern University
Anthony Elias, MDUniversity of Colorado School of Medicine
Mary Gemignani, MD, MPH Memorial Sloan Kettering Cancer Center
William Gradishar, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Nora Hansen, MD Robert H. LurieComprehensive Cancer Centerof Northwestern University
Dawn Hershman, MDHerbert Irving Comprehensive Cancer CenterColumbia University Mailman School of Public Health
Reshma Jagsi, MD, DPhil University of Michigan
Maxine Jochelson, MDMemorial Sloan Kettering Cancer Center
Virginia Kaklamani, MD, DScUT Health San Antonio MD Anderson Cancer Center
Steven Katz, MDUniversity of Michigan
Seema Khan, MD Robert H. LurieComprehensive Cancer Centerof Northwestern University
Tari King, MD Harvard Medical SchoolDana-Farber Cancer Institute
Sheetal Kircher, MDRobert H. LurieComprehensive Cancer Centerof Northwestern University
Connie Lehman, MD, PhDMassachusetts General Hospital
Sarah McLaughlin, MDMayo Clinic
Otto Metzger, MDHarvard Medical School Dana-Farber Cancer Institute
Tracy-Ann Moo, MDMemorial Sloan Kettering Cancer Center
Monica Morrow, MD Memorial Sloan Kettering Cancer Center
Jonas Nelson, MDMemorial Sloan Kettering Cancer Center
Lajos Pusztai, MD, DPhil Yale Cancer CenterYale School of Medicine
David Rimm, MD, PhDYale Cancer CenterYale School of Medicine
Stuart Schnitt, MDHarvard Medical SchoolDana-Farber Cancer Institute
Kalliopi Siziopikou, MD, PhD Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Jonathan Strauss, MD, MBA Robert H. LurieComprehensive Cancer Centerof Northwestern University
Julia White, MDThe Ohio State University Comprehensive Cancer Center
Kari Wisinski, MDUniversity of Wisconsin School of Medicine and Public Health
Faculty Disclosure Northwestern University FSM requires course directors, speakers, instructors, planners and other individuals who are in a position to control the content of this activity to disclose any relevant financial relationships. All identified potential conflicts of interest, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations are thoroughly vetted by Northwestern University FSM for fair balance. The faculty disclosures will be indicated in the course syllabus.